Bin Gao, Hua Wang, Fouad Lafdil, Dechun Feng  Journal of Hepatology 

Slides:



Advertisements
Similar presentations
INNATE IMMUNITY II.
Advertisements

Host – hepatitis C viral interactions: The role of genetics
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
Geoffrey W McCaughan, Amany Zekry  Journal of Hepatology 
Hepatic CD141+IFNλ+ DC subset: One against all?
The yin and yang of evasion and immune activation in HCC
Pathways of liver injury in alcoholic liver disease
The inflammasome in liver disease
Obesity, inflammation, and liver cancer
Geoffrey W McCaughan, Amany Zekry  Journal of Hepatology 
Hepcidin in human iron disorders: Therapeutic implications
Volume 52, Issue 3, Pages (March 2010)
Volume 142, Issue 4, Pages (April 2012)
Stem cell therapies for liver failure and cirrhosis
Agustín Albillos, Margaret Lario, Melchor Álvarez-Mon 
Hepatitis C-associated B-cell non-Hodgkin lymphomas
IL-6 pathway in the liver: From physiopathology to therapy
Mechanisms of action of interferon and nucleoside analogues
Roles for Chemokines in Liver Disease
Sterol-izing Innate Immunity
Volume 137, Issue 6, Pages e2 (December 2009)
Allogeneic hematopoietic cell transplant in HCV-infected patients
Telomeres and telomerase: new targets for the treatment of liver cirrhosis and hepatocellular carcinoma  André Lechel, Michael P. Manns, K.Lenhard Rudolph 
Ludger Scheja, Joerg Heeren  Journal of Hepatology 
Unraveling the Pros and Cons of Interferon-γ Gene Regulation
Histamine in the immune regulation of allergic inflammation
Hepatitis C core protein – The “core” of immune deception?
Signalling pathways in alcohol-induced liver inflammation
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
Simon Haas, Andreas Trumpp  Developmental Cell 
Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study.
Targeting gut flora to prevent progression of hepatocellular carcinoma
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Volume 53, Issue 4, Pages (October 2010)
Reciprocal regulation between hepcidin and erythropoiesis and its therapeutic application in erythroid disorders  Caiyi Wang, Zheng Fang, Zesen Zhu, Jing.
A dive into the complexity of type I interferon antiviral functions
The yin and yang of evasion and immune activation in HCC
Genomic risk of hepatitis C-related hepatocellular carcinoma
Pathways of liver injury in alcoholic liver disease
Volume 134, Issue 4, Pages (April 2008)
Met as a therapeutic target in HCC: Facts and hopes
Cannabinoid signaling and liver therapeutics
Senescence in chronic liver disease: Is the future in aging?
A View to Natural Killer Cells in Hepatitis C
Macrophages in Tissue Repair, Regeneration, and Fibrosis
Interleukin-28b: A Key Piece of the Hepatitis C Virus Recovery Puzzle
Claire Z. Larter, Geoffrey C. Farrell  Journal of Hepatology 
Volume 59, Issue 2, Pages (August 2013)
Death receptor-mediated apoptosis and the liver
Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman 
Nature's TRAIL—On a Path to Cancer Immunotherapy
miR-122 – A key factor and therapeutic target in liver disease
Kornelius Schulze, Jean-Charles Nault, Augusto Villanueva 
Volume 44, Issue 5, Pages (May 2006)
Schematic summary of the mechanisms by which tick-borne Phlebovirus NSs proteins inhibit the canonical IFN induction and signaling pathways. Schematic.
Innate immunity and HCV
Macrophage heterogeneity in liver injury and fibrosis
Volume 40, Issue 1, Pages (January 2004)
IL-7 Knocks the Socs Off Chronic Viral Infection
Primary immunodeficiencies may reveal potential infectious diseases associated with immune-targeting mAb treatments  László Maródi, MD, PhD, Jean-Laurent.
Eric Robinet, Thomas F. Baumert  Journal of Hepatology 
Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell–mediated allergic inflammation  Yong-Jun Liu, MD, PhD  Journal.
Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune Diseases  Xiaoyu Hu, Lionel B. Ivashkiv  Immunity 
Philippe Metz, Antje Reuter, Silke Bender, Ralf Bartenschlager 
Host – hepatitis C viral interactions: The role of genetics
Volume 137, Issue 6, Pages e2 (December 2009)
Volume 61, Issue 2, Pages (August 2014)
Immunity, Inflammation, and Cancer
Apoptosis: Activate NF-κB or die?
TAMpering with Toll-like Receptor Signaling
Presentation transcript:

STAT proteins – Key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver  Bin Gao, Hua Wang, Fouad Lafdil, Dechun Feng  Journal of Hepatology  Volume 57, Issue 2, Pages 430-441 (August 2012) DOI: 10.1016/j.jhep.2012.01.029 Copyright © 2012 Terms and Conditions

Fig. 1 Anti-viral effects of STAT1 and STAT2 in viral hepatitis. Virus-infected cells produce both IFN-α/β and IFN-λ, which bind to their corresponding receptors and activate STAT1 and STAT2 in human hepatocytes. Activated STAT1 and STAT2 induce many anti-viral proteins (e.g. Mx1, OAS, IRF-7, etc.) that subsequently inhibit HCV replication. Although IFN-α/β stimulation also induces strong STAT3 activation in hepatocytes [39], the role of STAT3 in the anti-viral activity of IFN-α/β against HCV remains unknown. IFN-α/β usually induces transient STAT1 and STAT2 activation. In contrast, IFN-λ induces prolonged STAT activation, which may be responsible for the protective effects of IFN-λ on spontaneous and treatment-induced HCV clearance. In addition, IFN-α therapy induces STAT1 activation in NK cells and subsequent NK cell activation. The activated NK cells may also contribute to the anti-viral effects of IFN-α therapy against HCV, which is needed to be confirmed by further studies. IFN-α also activates STAT1 in hematopoietic and neuronal cells that express both IFNAR1 and IFNAR2, resulting in the various side effects associated with IFN-α therapy. IFN-λR1 (IL-28R1) is largely restricted to hepatocytes and is not expressed on immune cells. Thus, IFN-λ treatment is less likely to induce the hematopoietic and neurological side effects associated with IFN-α therapy. IRF-9, interferon regulatory factor 9; ISGF3, interferon-stimulated gene factor 3 complex; ISRE, interferon-sensitive response element; ISG, interferon stimulated gene. Journal of Hepatology 2012 57, 430-441DOI: (10.1016/j.jhep.2012.01.029) Copyright © 2012 Terms and Conditions

Fig. 2 Hepatocyte STAT1 and STAT3 in liver injury, inflammation, and regeneration. While STAT1 in hepatocytes is predominantly activated by IFN-γ, STAT3 in hepatocytes is predominantly activated by IL-6, IL-6 family cytokines, and IL-22. Following activation, STAT1 dimerizes and translocates into the nucleus to induce the transcription of many genes that promote liver injury and inflammation and inhibit liver regeneration. In contrast, activated STAT3 induces the expression of many genes that mitigate liver injury and promote liver regeneration. Under most conditions, activation of hepatic STAT3 blocks liver inflammation by inhibiting pro-inflammatory STAT1 signaling and protecting against liver injury. However, hepatic STAT3 may also promote liver inflammation by inducing the production of hepatocyte-derived acute phase proteins. STAT1 and STAT3 in hepatocytes also negatively regulate one another through the induction of SOCS1 and SOCS3 proteins, respectively. ISG, Interferon Stimulated Gene; GAS, Interferon-Gamma Activated Sequence. Journal of Hepatology 2012 57, 430-441DOI: (10.1016/j.jhep.2012.01.029) Copyright © 2012 Terms and Conditions

Fig. 3 Hepatoprotective versus oncogenic functions of STAT3. During chronic liver injury, steatosis, and inflammation, IL-6, IL-6 family cytokines, and IL-22 induce STAT3 activation, leading to the upregulation of a variety of anti-apoptotic, anti-oxidative, and anti-steatogenic proteins in hepatocytes that prevent liver injury and inhibit injury-associated HCC initiation. IL-22 may have therapeutic potential in the treatment of liver failure (e.g. acute alcoholic hepatitis) and fatty liver disease. In contrast, during end-stage liver cirrhosis and liver cancer, STAT3 activation promotes tumor cell survival and proliferation and therefore HCC progression. Thus, STAT3 inhibitors may have therapeutic potential in the treatment of HCC. Journal of Hepatology 2012 57, 430-441DOI: (10.1016/j.jhep.2012.01.029) Copyright © 2012 Terms and Conditions

Journal of Hepatology 2012 57, 430-441DOI: (10. 1016/j. jhep. 2012. 01 Copyright © 2012 Terms and Conditions